This article is more than 5 years old. Information may no longer be current.
Study: Use of ophthalmic solution showed significant improvement in visual acuity
Click Here to Manage Email Alerts
SAN DIEGO — Most patients who received bromfenac sodium ophthalmic solution 0.09% once a day had a statistically significant improvement in visual acuity up to day 22 compared with a placebo group, a study found.
On day 22, 87% of the bromfenac subjects had an improvement in visual acuity of one line or more (P < .0001) and 56% had an improvement of three lines or more (P < .005) compared with placebo, Bonnie An Henderson, MD, an OSN Cataract Surgery Board Member, and colleagues said in a poster study presented at the American Society of Cataract and Refractive Surgery meeting here.
The study looked at two groups of patients who underwent ocular surgery and had either bromfenac sodium ophthalmic solution 0.09% (Ista Pharmaceuticals) or a placebo once a day in the study eye. The bromfenac-dosed group was comprised of 559 patients; the placebo group was comprised of 278 patients.
All patients underwent safety evaluations on days 1, 3, 8, 15 and 22, in addition to an evaluation of their visual acuity with the Snellen eye chart.
The study was part of the drug's phase 3 clinical trials.
- Disclosure: Dr. Henderson is principal investigator of the bromfenac sodium ophthalmic solution 0.09% clinical trials, and her co-authors are either fellow principal investigators or employees of Ista Pharmaceuticals.